CGRP Forum is made possible thanks to support from AbbVie, Lilly, Organon and Pfizer, all of whom have no influence or control of editorial content. More information is available here »
Migraine care in Brazil: the role of anti-CGRP therapies is a new slide deck summarising clinical trial and real world data, with links to key references. Although focusing on use of CGRP monoclonal antibodies in Brazil, it includes an update of key clinical results with erenumab, fremanezumab, galcanezumab and eptinezumab that is relevant to clinicians around the world who are treating migraine.
This program is funded in part via an independent educational grant from AbbVie.
Organon has provided sponsorship towards this independent resource. Organon has had no editorial input or control over content, nor opportunity to influence.
Financial support was provided as GMG Knowledge Gap Grant from Pfizer Inc, Pfizer have provided only financial support and had no input into the content provided.
